Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22955796 | 0.86 | TSHR (0.49) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL2173910 | 0.84 | TSHR (0.50) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL4867753 | 0.83 | CES2 (0.52) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL1925969 | 0.81 | TSHR (0.47) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL3732383 | 0.80 | CES2 (0.58) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL3181932 | 0.80 | CES2 (0.58) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL15120382 | 0.79 | CES2 (0.56) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL4498835 | 0.77 | TSHR (0.48) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL31388183 | 0.77 | TSHR (0.44) | TSHRALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL7037574 | 0.76 | CES2 (0.58) | TSHRALDH1A1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-7659411-B2 | Process for producing 2-acylthiophene compound | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070149787-A1 | Process for producing 2-acylthiophene compound | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1695972-A1 | PROCESS FOR PRODUCING 2-ACYLTHIOPHENE COMPOUND | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149787-A1 | Process for producing 2-acylthiophene compound | AGPAT2, MOGAT2, TPST2 | TSHR 1217/4885ALDH1A1 111/4885NPC1 3154/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | TSHR 1343/4885ALDH1A1 2036/4885NPC1 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.